Precision BioSciences (DTIL) Stock Stalls After Q3 Earnings Loss Narrows

Precision BioSciences slipped into Q3 2026 earnings with a bruised recent tape and a stock that has drifted over the past quarter, yet the first reaction today is almost flat. The share price ticked only 0.3% higher to US$6.97, even as the gene editing specialist reported another quarterly loss but a much smaller one than earlier this year, with basic earnings per share for Q3 at a loss of US$0.28 and net income at a loss of US$7.6 million.

In the short term, that looks like a shrug. Over a multi-year view, investors are wrestling with a business that still carries losses but sits on trailing revenue of just over US$45 million and trades on a P/S multiple that is materially below both biotech peers and the wider industry.

Like the Precision BioSciences story but uneasy about a loss-making Q3 and a languishing share price? Compare this setup with a curated group of stronger balance sheet opportunities in our list of solid balance sheet and fundamentals stocks (23 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$0.0 million vs. US$0.013 million (reported sales remain very low in both periods)
• Net Income/Loss (Q3 2026 vs. Q3 2025): loss of US$7.586 million vs. loss of US$21.772 million (smaller quarterly loss year on year)
• Basic EPS (Q3 2026 vs. Q3 2025): loss of US$0.28 per share vs. loss of US$1.84 per share (loss per share narrowed compared with the prior comparable period)
• Trailing 12-Month Revenue (to Q3 2026 vs. to Q3 2025): US$45.042 million vs. US$0.698 million (very large increase in reported revenue on the trailing 12-month view)

Revenue is forecast to surge while losses continue. Ask Charlie what makes Precision BioSciences look cheap on sales.

Evaluating Precision BioSciences’ Multi‑Asset Bull Case

The optimistic view depends on Precision BioSciences turning early science into a real multi asset platform.

"The main requirement for this thesis is for PBGENE-HBV and PBGENE-DMD to convert current mechanistic, preclinical and early clinical signals into acceptable safety and efficacy profiles in larger trials within the current cash runway."

Q3 results show some financial progress, with the quarterly loss narrowing to US$7.6 million and loss per share improving to US$0.28. Trailing 12 month revenue of US$45.0 million versus very limited quarterly sales underlines that partnership and non recurring income are already material. The share price reaction, which was approximately flat, suggests investors see some thesis boxes being ticked but are not yet treating HBV, DMD or partnered data as fully de risked milestones.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Precision BioSciences Bear Case Meets Slower Milestones

The cautious view argues that Precision BioSciences will be held back by safety baggage and schedule risk rather than raw science.

"While repeat dosing of PBGENE‑HBV has not produced further Grade 3 hypotension after mitigation steps, the earlier possibly related intracerebral hemorrhage highlights the risk that regulators or investigators may tighten eligibility and dosing rules. This could cap patient volumes and delay HBV trial completion, with knock on effects for future earnings timing."

The latest quarter does not clear that hurdle. Revenue remains minimal at US$0.0 million and losses are still US$7.6 million, so there is no sign yet that HBV progress is converting into broader trial scale or commercial traction.

Hunt For Quiet Mispricings

Precision BioSciences just reported a narrower loss and saw a muted share price reaction. The real opportunity could sit in companies where fundamentals and valuation appear to have started to drift apart.

• Company 1 - 45% below our estimate - co-designs complex hardware for clients seeking collaboration from first sketch through full production.
• Company 2 - 38% below our estimate - adds high horsepower engine capacity to support long term power projects linked to data center demand.
• Company 3 - 48% below our estimate - expands a digital first drink network as dense store openings test delivery and technology investment capacity.

That is three of the list. See all 35 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com